Table 1.

The number of tumors, and wet weight of tumors, pituitaries, and uteri of OVX rats administered vehicle or DMBA, and vehicle, E₂ and/or raloxifene

DMBA condition	E2 condition	n	# tumors	Tumor weight (mg)	Pituitary Weight (mg)	Uterine weight (mg)
vehicle	Vehicle	8	0.5 ± 0.3	16 ± 3	12 ± 1	56 ± 6
	E2	7	1.0 ± 0.3	20 ± 6	14 ± 3+	112 ± 32*
	Raloxifene	7	0.8 ± 0.3	22 ± 4	13 ± 1	73 ± 11
	E2 + raloxifene	7	1.7 ± 0.5*	20 ± 4	14 ± 1+	113 ± 15*
DMBA	Vehicle	8	1.5 ± 0.3^	24 ± 4#	11 ± 1	53 ± 8
	E2	8	1.4 ± 0.3^	30 ± 3#	14 ± 1+	163 ± 15*
	Raloxifene	10	1.2 ± 0.2^	18 ± 3#	12 ± 1	67 ± 6
	E2 + raloxifene	10	1.8 ± 0.1^*	25 ± 2#	15 ± 1+	130 ± 14*

Values are mean ± SEM.

^{^}indicates significant effect of DMBA vs. no carcinogen exposure (P≤0.05).

^#indicates a tendency for DMBA to have a significant effect versus no carcinogen exposure (P≤0.10)

^*indicates significant effect of E₂ or E₂+raloxifene versus vehicle or raloxifene alone (P≤0.05).

⁺indicates significant effect of E₂ or E₂+raloxifene versus vehicle (P≤0.05).